PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.30
Negative OCF/share while Biotechnology median is -0.26. Seth Klarman would examine if a turnaround is realistic.
-0.30
Negative FCF/share while Biotechnology median is -0.30. Seth Klarman would question if the business is too capex-heavy.
-0.21%
Negative ratio while Biotechnology median is -0.38%. Seth Klarman would examine if negative OCF or unusual accounting drives this figure.
0.73
Ratio near Biotechnology median of 0.75. Charlie Munger might see standard alignment across the industry.
-6822.81%
Negative ratio while Biotechnology median is 0.00%. Seth Klarman would suspect deeper operational issues or near-zero revenue.